Approval Received for Marketing Authorization of Edoxaban Tosylate API
November 25, 2025
Source: drugdu
70
Jiuzhou PharmaceuticalThe announcement states that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. received chemical raw materials from the National Medical Products Administration.The company recently received the Approval Notice for Marketing Authorization of its chemical active pharmaceutical ingredient, edoxaban tosylate. This oral anticoagulant is primarily used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism. This approval indicates that the active pharmaceutical ingredient meets the relevant requirements for national drug registration and will further enrich the company's product portfolio and enhance its market competitiveness. The above matters will not have a significant impact on the company's performance in the short term.
https://finance.eastmoney.com/a/202511243572990379.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
